ETC
ITOS

Exchange Traded Concepts’s iTeos Therapeutics ITOS Stock Holding History

Exchange Traded Concepts’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-17,308
Closed -$103K – 1462
2025
Q1 		$103K Buy
17,308
+3,468
+25% +$25.5K ﹤0.01% 1151
2024
Q4 		$106K Hold
13,840
– – ﹤0.01% 1133
2024
Q3 		$141K Sell
13,840
-6,414
-32% -$97.9K ﹤0.01% 1084
2024
Q2 		$301K Sell
20,254
-6,301
-24% -$90.3K 0.01% 824
2024
Q1 		$362K Buy
26,555
+15,176
+133% +$165K 0.01% 726
2023
Q4 		$125K Buy
11,379
+2,885
+34% +$28.6K ﹤0.01% 857
2023
Q3 		$93K Sell
8,494
-1,130
-12% -$14.4K ﹤0.01% 923
2023
Q2 		$127K Buy
+9,624
New +$137K ﹤0.01% 891
2023
Q1 		– Sell
-28,531
Closed -$557K – 1208
2022
Q4 		$557K Buy
28,531
+950
+3% +$18.6K 0.02% 498
2022
Q3 		$525K Buy
27,581
+5,703
+26% +$131K 0.02% 460
2022
Q2 		$451K Buy
21,878
+766
+4% +$18.2K 0.01% 558
2022
Q1 		$679K Buy
+21,112
New +$767K 0.01% 423

Other funds holding ITOS

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Exchange Traded Concepts's ITOS Position: Q2 2025 in Review

Exchange Traded Concepts sold out of iTeos Therapeutics (ITOS) in Q2 2025, closing a stake of 17,308 shares — an estimated $103K sold.

Exchange Traded Concepts first reported a position in ITOS in Q1 2022 and held it in 12 quarters. The position peaked at $679K in Q1 2022. 136 funds tracked by Wall St. Rank hold ITOS as of Q2 2025.

  • Exchange Traded Concepts reported no remaining iTeos Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Exchange Traded Concepts sold 17,308 iTeos Therapeutics shares in Q2 2025, an estimated $103K.
  • Exchange Traded Concepts first reported a position in iTeos Therapeutics in Q1 2022 and held it in 12 quarters.
  • Exchange Traded Concepts's iTeos Therapeutics position peaked at $679K in Q1 2022.
  • 136 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q2 2025.

Based on Exchange Traded Concepts's 13F filing for Q2 2025, filed 10 Jul 2025.